Home › Research › Down syndrome and Alzheimer's
Change in plasma Aß peptides and onset of dementia in adults with Down syndrome
Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, Silverman W.. Neurology, 2010-11-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Objective To examine changes in levels of plasma amyloid-β (Aβ) peptides, Aβ42 and Aβ40, in relation to onset of Alzheimer disease (AD) in adults with Down syndrome (DS). Methods Plasma Aβ42 and Aβ40 were measured at initial examination and at follow-up in a community-based cohort of 225 adults with DS who did not have dementia at baseline and were assessed for cognitive/functional abilities and health status and followed at 14- to 20-month intervals. We used Cox proportional hazards modeling to estimate the cumulative incidence of AD by Aβ peptide change group (increasing, no change, or decreasing), adjusting for covariates. Results Sixty-one (27.1%) of the participants developed AD. At follow-up, a decrease in Aβ42 levels, a decrease in the Aβ42/Aβ40 ratio, and an increase in Aβ40 levels were related to conversion to AD. Compared with the group with increasing levels of Aβ42, the likelihood of developing AD was 5 times higher for those whose plasma Aβ42 levels decreased over follow-up (hazard ratio [HR] = 4.9, 95% confidence interval [CI] 2.1-11.4). Decreasing Aβ42/Aβ40 was also strongly related to AD risk (HR = 4.9, 95% CI 1.8-13.2), while decreasing Aβ40 was associated with lower risk (HR = 0.4, 95% CI 0.2-0.9). Conclusions Among adults with DS, decreasing levels of plasma Aβ42, a decline in the Aβ42/Aβ40 ratio, or increasing levels of Aβ40 may be sensitive indicators of conversion to AD, possibly reflecting compartmentalization of Aβ peptides in the brain.
What this study adds
Evidence grade: Moderate
The record lists 225 participants. In 225 adults with Down syndrome without dementia at baseline, 61 (27.1%) developed Alzheimer's disease, and a decrease in plasma Abeta42 levels or in the Abeta42/Abeta40 ratio, or an increase in Abeta40 levels, were related to conversion to Alzheimer's disease. Reported effect size: 27.1%; HR = 4.9; HR = 0.4.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schupf, N., Zigman, W. B., Tang, M. X., Pang, D., Mayeux, R., Mehta, P., et al. (2010). Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology. https://doi.org/10.1212/wnl.0b013e3181fb448b
Vancouver
Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, et al. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology. 2010. doi:10.1212/wnl.0b013e3181fb448b. PMID: 21041786.
BibTeX
@article{schupf2010-21041786,
author = {Schupf, N. and Zigman, W. B. and Tang, M. X. and Pang, D. and Mayeux, R. and Mehta, P. and Silverman, W.},
title = {{Change in plasma Aß peptides and onset of dementia in adults with Down syndrome}},
journal = {Neurology},
year = {2010},
doi = {10.1212/wnl.0b013e3181fb448b},
pmid = {21041786},
url = {https://doi.org/10.1212/wnl.0b013e3181fb448b}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Sixty-one (27.1%) of the participants developed AD.
- Compared with the group with increasing levels of Aβ42, the likelihood of developing AD was 5 times higher for those whose plasma Aβ42 levels decreased over follow-up (hazard ratio [HR] = 4.9, 95% confidence interval [CI] 2.1-11.4).
- Decreasing Aβ42/Aβ40 was also strongly related to AD risk (HR = 4.9, 95% CI 1.8-13.2), while decreasing Aβ40 was associated with lower risk (HR = 0.4, 95% CI 0.2-0.9).
Why it matters
In 225 adults with Down syndrome without dementia at baseline, 61 (27.1%) developed Alzheimer's disease, and a decrease in plasma Abeta42 levels or in the Abeta42/Abeta40 ratio, or an increase in Abeta40 levels, were related to conversion to Alzheimer's disease. The authors conclude these changes may be sensitive indicators of conversion.
Study details
- Participants225
- Effect size27.1%; HR = 4.9; HR = 0.4
- Evidence strengthModerate
How this study scored 54/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 225 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 81 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.5 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 3 / 6 | Cited 4.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Wayne P. Silverman: h-index 50 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Columbia University Irving Medical Center: institution h-index 1,047 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21041786) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.